• Liuer He, Huiyu Li, Anqi Wu, Yulong Peng, Guang Shu, and Gang Yin.
• Department of Pathology, Xiangya Hospital, School of Basic Medical Sciences, Central South University, Changsha, 410008, Hunan Province, China.
• Mol Cancer. 2019 Dec 4; 18 (1): 176.

AbstractN6-methyladenosine (m6A) is methylation that occurs in the N6-position of adenosine, which is the most prevalent internal modification on eukaryotic mRNA. Accumulating evidence suggests that m6A modulates gene expression, thereby regulating cellular processes ranging from cell self-renewal, differentiation, invasion and apoptosis. M6A is installed by m6A methyltransferases, removed by m6A demethylases and recognized by reader proteins, which regulate of RNA metabolism including translation, splicing, export, degradation and microRNA processing. Alteration of m6A levels participates in cancer pathogenesis and development via regulating expression of tumor-related genes like BRD4, MYC, SOCS2 and EGFR. In this review, we elaborate on recent advances in research of m6A enzymes. We also highlight the underlying mechanism of m6A in cancer pathogenesis and progression. Finally, we review corresponding potential targets in cancer therapy.

27 keywords...

hide…